View Older Stories

May 8, 2026 08:00AM Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Apr 16, 2026 08:04AM Ensysce receives approval for final phase of opioid overdose study

Apr 16, 2026 08:00AM Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Apr 9, 2026 06:13AM Ensysce Biosciences (ENSC) files for 20.34M share offering by selling stockholders

Apr 7, 2026 08:17AM Ensysce Biosciences closes $2 million financing tranche

Apr 7, 2026 08:00AM Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Mar 31, 2026 06:51AM Ensysce Biosciences (ENSC) Misses Q4 EPS by 75c

Mar 30, 2026 04:50PM Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026 08:45AM Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Mar 3, 2026 08:02AM Ensysce Biosciences publishes clinical data on overdose protection technology

Mar 3, 2026 08:00AM Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Feb 25, 2026 08:00AM Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Feb 23, 2026 08:00AM Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Jan 28, 2026 08:02AM Ensysce reaches 50% enrollment in phase 3 trial for opioid PF614

Jan 28, 2026 08:00AM Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Jan 21, 2026 08:03AM Ensysce Biosciences receives Brazil patent for opioid technologies

Jan 21, 2026 08:00AM Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 8, 2026 08:00AM Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 5, 2026 08:03AM Ensysce secures up to $20 million in funding, advances phase 3 opioid trial

Jan 5, 2026 08:00AM Ensysce Biosciences Issues Annual Shareholder Letter

Dec 9, 2025 08:00AM Ensysce begins Phase 3 trial enrollment for pain drug PF614

Dec 9, 2025 08:00AM Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 2, 2025 08:05AM Ensysce receives patent allowance for MPAR overdose protection technology

Dec 2, 2025 08:00AM Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Nov 20, 2025 08:00AM Ensysce Biosciences receives FDA approval for PF614 manufacturing approach

Nov 20, 2025 08:00AM Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 17, 2025 08:06AM Ensysce Biosciences raises $4 million in convertible financing round

Nov 17, 2025 08:05AM Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 16, 2025 11:46PM Ensysce Biosciences (ENSC) reported Q3 EPS

Nov 14, 2025 04:15PM Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Sep 4, 2025 08:00AM Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025 08:00AM Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 13, 2025 06:15PM Ensysce Biosciences (ENSC) Misses Q2 EPS by 79c

Aug 13, 2025 04:15PM Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Jul 31, 2025 08:00AM Ensysce receives FDA guidance on opioid with overdose protection

Jul 31, 2025 08:00AM Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025 08:00AM Ensysce Biosciences begins phase 3 trial for abuse-resistant opioid PF614

Jul 16, 2025 08:00AM Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025 08:00AM Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025 08:00AM Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025 08:12AM Ensysce Biosciences (ENSC) Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Jun 4, 2025 08:00AM Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 14, 2025 04:58PM Ensysce Biosciences (ENSC) Misses Q1 EPS by 139c

May 13, 2025 04:15PM Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 12, 2025 08:00AM Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Apr 24, 2025 04:15PM Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025 04:44PM Ensysce Biosciences (ENSC) Announces Exercise of Warrants for $2.2M Gross Proceeds

Apr 23, 2025 04:41PM Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025 08:04AM Ensysce Biosciences (ENSC) Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 23, 2025 08:00AM Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

View Older Stories